This inventor holds 1 USPTO granted patent. Top assignee: National Cheng-Kung University. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Innovations by Chia Jui Yen in Hepatitis B Virus Research
Introduction
Chia Jui Yen is a notable inventor based in Tainan, Taiwan. He has made significant contributions to the field of medical research, particularly in the area of hepatitis B virus (HBV) detection and treatment. His innovative work has the potential to improve the diagnosis and management of chronic liver diseases.
Latest Patents
Chia Jui Yen holds a patent for a "Kit of in vitro quantifying large surface protein of hepatitis B virus (HBV), biomarker set for analyzing phases of HBV infection and hepatoma prognosis, and set of monoclonal antibodies for predicting, diagnosing or treating chronic liver disease." This invention relates to a kit designed to quantify the large surface protein of HBV. The kit includes monoclonal antibodies that have specific binding affinities for various regions of the large surface protein, enhancing the sensitivity and dynamic range of detection in biological samples. Additionally, the invention provides a biomarker set that can be recognized by these antibodies, allowing for non-invasive analysis of HBV infection phases and hepatoma prognosis. Furthermore, it offers a set of monoclonal antibodies aimed at predicting, diagnosing, or treating chronic liver diseases.
Career Highlights
Chia Jui Yen is affiliated with National Cheng-kung University, where he conducts his research and development activities. His work has garnered attention for its innovative approach to tackling complex medical challenges associated with hepatitis B virus infections.
Collaborations
Chia Jui Yen collaborates with esteemed colleagues such as Wen Ya Huang and Yun-Ping Lee. Their combined expertise contributes to the advancement of research in the field of virology and liver disease.
Conclusion
Chia Jui Yen's contributions to hepatitis B virus research through his innovative patent demonstrate his commitment to improving healthcare outcomes. His work not only enhances the understanding of HBV but also provides valuable tools for diagnosis and treatment.